MX2021000908A - Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. - Google Patents

Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.

Info

Publication number
MX2021000908A
MX2021000908A MX2021000908A MX2021000908A MX2021000908A MX 2021000908 A MX2021000908 A MX 2021000908A MX 2021000908 A MX2021000908 A MX 2021000908A MX 2021000908 A MX2021000908 A MX 2021000908A MX 2021000908 A MX2021000908 A MX 2021000908A
Authority
MX
Mexico
Prior art keywords
breathlessness
dyspnea
treatment
chronic cough
cough
Prior art date
Application number
MX2021000908A
Other languages
English (en)
Inventor
Thomas Sciascia
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of MX2021000908A publication Critical patent/MX2021000908A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para tratar a pacientes con tos crónica con composiciones de nalbufina, así como para tratar la tos, la dificultad respiratoria o la disnea asociadas con la IPF con composiciones de nalbufina, en donde el método proporciona un efecto terapéutico en un paciente.
MX2021000908A 2018-07-23 2019-07-23 Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. MX2021000908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701902P 2018-07-23 2018-07-23
PCT/US2019/042994 WO2020023486A1 (en) 2018-07-23 2019-07-23 Treatment of chronic cough, breathlessness and dyspnea

Publications (1)

Publication Number Publication Date
MX2021000908A true MX2021000908A (es) 2021-06-08

Family

ID=69162461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000908A MX2021000908A (es) 2018-07-23 2019-07-23 Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.

Country Status (12)

Country Link
US (3) US20200022974A1 (es)
EP (1) EP3826635A4 (es)
JP (1) JP2021531299A (es)
KR (1) KR20210035854A (es)
CN (1) CN112703000B (es)
AU (1) AU2019309913A1 (es)
BR (2) BR112021001177A2 (es)
CA (1) CA3106995A1 (es)
IL (1) IL280301A (es)
MX (1) MX2021000908A (es)
SG (1) SG11202100580UA (es)
WO (1) WO2020023486A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210035854A (ko) 2018-07-23 2021-04-01 트레비 테라퓨틱스, 인코포레이티드 만성 기침, 무호흡증 및 호흡곤란의 치료
JP2023510341A (ja) * 2020-01-10 2023-03-13 トレビ セラピューティクス インコーポレイテッド ナルブフィン投与メソッド

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443442A (en) 1979-12-21 1984-04-17 Skillern Scott D Method and composition for treatment of acne vulgaris
JPS59501712A (ja) 1982-08-25 1984-10-11 バ−ンステイン，ジヨエル　イ−． 「そう」痒症を治療する方法およびそのための組成物
US4720384A (en) 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
EP1312361A1 (en) 1996-11-25 2003-05-21 Toray Industries, Inc. Antipruritic agent
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
WO1999003459A1 (en) 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
JP2001163784A (ja) 1999-12-06 2001-06-19 Toray Ind Inc 角膜または結膜用止痒剤
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
JP4370683B2 (ja) 2000-05-08 2009-11-25 東レ株式会社 そう痒疾患の検査方法
DE10116978A1 (de) 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
ITMI20010907A1 (it) 2001-05-02 2002-11-02 Valpharma Sa Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi
US20030054030A1 (en) 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
DK1436012T3 (en) 2001-10-18 2018-01-22 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
US6703398B2 (en) 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1639997A1 (en) 2002-04-05 2006-03-29 Euro-Celtique S.A. Matrix for sustained, invariant and independant release of active compounds
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
SI2263691T1 (sl) 2002-07-15 2012-12-31 F. Hoffmann-La Roche Ag Zdravljenje raka z rekombinantnim humaniziranim monoklonskim anti-ErbB2 protitelesom 2C4 (rhuMAb 2C4)
CA2490758C (en) 2002-07-15 2014-09-23 Genentech, Inc. Dosage form of recombinant humanized monoclonal antibody 2c4
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
WO2005032555A2 (en) 2003-09-25 2005-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
WO2005094826A1 (ja) 2004-03-30 2005-10-13 Toray Industries, Inc. 止痒剤
EP1763349A2 (en) 2004-06-03 2007-03-21 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
PT1888033E (pt) 2005-06-09 2014-05-15 Meda Ab Método e composição para tratamento de distúrbios inflamatórios
EP2402005B1 (en) * 2005-08-24 2020-12-16 Endo Pharmaceuticals Inc. Sustained release formulations of nalbuphine
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
JP2009506080A (ja) 2005-08-30 2009-02-12 クィーンズ ユニバーシティー アット キングストン 超低用量のα−２−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および／またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法
RU2565391C2 (ru) 2006-01-10 2015-10-20 Займоджинетикс, Инк. Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
JP2008109898A (ja) 2006-10-31 2008-05-15 Toray Ind Inc 鎮痒作用を有する化合物のスクリーニング方法
MX2009005000A (es) 2006-11-10 2009-10-12 Cara Therapeutics Inc Amidas de peptidos sinteticos.
BRPI0719305A2 (pt) 2006-11-22 2014-02-04 Progenics Pharm Inc (r)-n-estereoisômeros de análogos de 7,8-saturados-4,5-epóxi-morfinano
EP2099456A2 (en) 2006-11-22 2009-09-16 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
MX2009005460A (es) 2006-11-22 2009-08-28 Progenics Pharm Inc (s)-n-estereoisomeros de analogos de 7,8-saturados-4,5-epoxi-morfi nano.
US20080207667A1 (en) * 2007-02-23 2008-08-28 Rhame Robert W Use of nalbuphine and related compounds to treat symptoms of respiratory problems
AU2008233129B2 (en) 2007-03-29 2014-03-20 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
PL2136801T3 (pl) 2007-03-30 2013-01-31 Tioga Pharmaceuticals Inc Agoniści kappa-opioidów do leczenia zespołu jelita drażliwego w postaci zmiennej i z dominującą biegunką
WO2008129000A1 (en) 2007-04-20 2008-10-30 Novartis Ag Pyridopyrimidine derivatives and use thereof in the treatment of itch and itch related disorders
WO2008128892A1 (en) 2007-04-23 2008-10-30 Symrise Gmbh & Co. Kg Polyethylene glycol esters and cosmetic and/or dermatological preparations
BRPI0813230A2 (pt) 2007-06-28 2014-12-23 Novartis Ag Moduladores de calicreína 7
CA2714921C (en) 2007-09-04 2016-04-05 Alpharma, Inc. Pharmaceutical compositions
US20090093509A1 (en) 2007-10-08 2009-04-09 Tahir Nazir Methods and Compositions for the Treatment of Pruritus
WO2009070733A1 (en) 2007-11-26 2009-06-04 Pharmacofore, Inc. Peripheral phenolic opioid antagonist
JP2011512360A (ja) 2008-02-14 2011-04-21 アルカーメス，インコーポレイテッド 選択的オピオイド化合物
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
WO2009132313A2 (en) 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
CA2740440A1 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
JP5425229B2 (ja) 2009-02-24 2014-02-26 ノバルティス アーゲー Ｎｋ受容体アンタゴニストの使用
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
AU2009342654B2 (en) 2009-03-19 2013-09-05 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
US20120040009A1 (en) 2009-04-22 2012-02-16 Lars Holger Hermann Particulate pharmaceutical composition with an opioid and an opioid antagonist
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
CA2709800C (en) * 2009-07-15 2023-01-10 Universite Laval Method and device for administering oxygen to a patient and monitoring the patient
AU2011211223B2 (en) 2010-01-29 2014-10-23 Toray Industries, Inc. Therapeutic or prophylactic agent for biliary diseases
IT1398930B1 (it) 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
FR2963889B1 (fr) 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
JP2012087101A (ja) 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
RU2015128265A (ru) * 2012-12-14 2017-01-25 Треви Терапьютикс, Инк. Способы лечения зуда
WO2015027212A1 (en) * 2013-08-23 2015-02-26 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
AU2015274327A1 (en) 2014-06-13 2017-01-05 Trevi Therapeutics, Inc. Methods for treating pruritus
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
WO2017108041A1 (en) * 2015-12-23 2017-06-29 Conrig Pharma Aps Suplatast tosilate for treating cough associated with interstitial lung disease
US20170216277A1 (en) 2016-01-06 2017-08-03 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
ES2738678T3 (es) * 2016-01-08 2020-01-24 Nerre Therapeutics Ltd Orvepitant para el tratamiento de la tos crónica
CN105560202B (zh) 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
BR112018069174A2 (pt) 2016-03-21 2019-01-29 Trevi Therapeutics Inc tratamento de prurido urêmico
WO2018013788A1 (en) * 2016-07-14 2018-01-18 Children's Hospital Medical Center Methods for treating fibrosis
EP3506893A4 (en) * 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
EP3532061A4 (en) 2016-10-25 2020-07-08 Trevi Therapeutics, Inc. TREATMENT OF PRURIGO NODULAR
JP2021532080A (ja) 2018-07-11 2021-11-25 トレビ セラピューティクス インコーポレイテッド 肝疾患の掻痒症状の治療
KR20210035854A (ko) 2018-07-23 2021-04-01 트레비 테라퓨틱스, 인코포레이티드 만성 기침, 무호흡증 및 호흡곤란의 치료

Also Published As

Publication number Publication date
SG11202100580UA (en) 2021-02-25
US11660296B2 (en) 2023-05-30
US20220409613A1 (en) 2022-12-29
EP3826635A4 (en) 2022-04-27
CN112703000A (zh) 2021-04-23
BR112021001177A2 (pt) 2021-04-27
US20200022974A1 (en) 2020-01-23
IL280301A (en) 2021-03-01
BR122023024228A2 (pt) 2024-02-20
JP2021531299A (ja) 2021-11-18
EP3826635A1 (en) 2021-06-02
US20220218697A1 (en) 2022-07-14
CA3106995A1 (en) 2020-01-30
KR20210035854A (ko) 2021-04-01
CN112703000B (zh) 2024-05-31
AU2019309913A1 (en) 2021-03-11
WO2020023486A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MY190034A (en) Method of treating cancer associated with a ras mutation
ZA201804513B (en) Method of treating c3 glomerulopathy
MX2017010150A (es) Bacterias probioticas recombinantes.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
EP3488877A4 (en) IMPLANT AND KIT FOR TREATING BONE LESION SITES AND METHOD FOR TREATING LESION SITES
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2023008193A (es) Procedimientos para tratar el cáncer.
IL267958B1 (en) An injectable preparation that can be used to treat heart diseases and contains fibroblasts, and a method for producing fibroblasts for medical use
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2021000908A (es) Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2018013943A (es) Metodo de tratamiento de hiperglucemia.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018011379A (es) Tratamiento del prurito uremico.
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.